anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Image

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 119,566
Current window 89,011-89,040
Pages 3,986
Rows per page 30
Component: Imageclear collectionreset all
18 30 60

Component

89,011-89,040 of 119,566

filter-aware
86
The slide uses molecular visualization of RBD mutations and a table showing KD (binding affinity) values, highlighting the poor binding (607 nM) to the beta variant.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
87
The slide uses a two-step process flow (1 and 2) to explain the technical methodology of their AI-driven drug discovery platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
90
The slide uses a process diagram to show the AI workflow and a table to quantify the binding affinity (nM KD) improvements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
92
The slide uses a 5-column layout with icons to represent different capabilities of the platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
93
Includes pseudo-code snippets in the background.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
97
Includes a biological pathway diagram (Takedatsu 2008) and market data points.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
102
Includes a Kaplan-Meier survival curve and a biological diagram of TLS.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
109
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
110
The slide uses code snippets as decorative background elements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
111
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
01
Slide 1
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a horizontal bar chart to represent the development stage of each program.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
08
The slide features a stylized antibody graphic overlaid on a dark blue/purple abstract background.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a structural biology visualization and two dose-response curves to establish bio-equivalence and differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
19
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
20
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
25
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
26
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
36
The slide details a corporate M&A event and subsequent private placement financing.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a three-column layout to present the company's core technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses a split-screen layout with a photo of a person on the right and branding on the left.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
10
Includes structural biology visualization, dose-response curves, and a binding affinity table.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
15
Uses icon-based visualization to represent injection frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
20
Features a stylized antibody icon overlay on a photo of a person.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
27
The graphic overlays on the photo are stylized representations of antibodies, suggesting a biotech/pharma context.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
32
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
33
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
37
This slide outlines the M&A transaction details including a $210M private placement.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit